Kamran Alam
Directeur Financier/CFO chez TAYSHA GENE THERAPIES, INC.
Fortune : 364 313 $ au 30/04/2024
Profil
Kamran Alam is currently the Chief Financial Officer & Secretary at Taysha Gene Therapies, Inc. Prior to this, he held positions as Finance Director at Naurex, Inc., Senior Director-Finance & Accounting at Aptinyx, Inc., Vice President-Finance at Novartis Gene Therapies, Inc., and Chief Financial Officer & Senior Vice President at Rocket Pharmaceuticals, Inc. He completed his undergraduate degree at Stephen M.
Ross School of Business and holds an MBA from Kelley School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2024 | 158 397 ( 0,08% ) | 364 313 $ | 30/04/2024 |
Postes actifs de Kamran Alam
| Sociétés | Poste | Début |
|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Directeur Financier/CFO | 01/08/2020 |
Anciens postes connus de Kamran Alam
| Sociétés | Poste | Fin |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Directeur Financier/CFO | 01/07/2020 |
| AVEXIS INC | Corporate Officer/Principal | 01/10/2019 |
| APTINYX | Comptroller/Controller/Auditor | 01/04/2016 |
Naurex, Inc.
 Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Corporate Officer/Principal | - |
Formation de Kamran Alam
| Kelley School of Business | Masters Business Admin |
| Stephen M. Ross School of Business | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| APTINYX | Health Technology |
| TAYSHA GENE THERAPIES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Health Technology |